Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail shows promise for Hard-to-Treat breast cancer

NCT ID NCT05583110

Terminated Disease control Sponsor: Spanish Breast Cancer Research Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of three drugs—tucatinib, trastuzumab, and vinorelbine—in 13 people with HER2-positive breast cancer that had spread or could not be surgically removed. The goal was to see how many patients' tumors shrank or disappeared. The trial was terminated early, so the full results are not available, but early data may help guide future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tucatinib (Tukysa) combined with trastuzumab and vinorelbine
What this could lead to
If successful, this combination could offer a new treatment option for people with HER2-positive breast cancer that has spread or cannot be removed by surgery.
What could go wrong
This was a small, early-phase trial that ended early, so results are limited. The combination may not work better than existing treatments and could cause side effects like diarrhea or low blood cell counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-POSITIVE METASTATIC BREAST CANCER LOCALLY ADVANCED HER2-POSITIVE BREAST CARCINOMA

Contacts and locations

Locations

  • Complejo hospitalario Universitario Insular-Materno Infantil

    Las Palmas de Gran Canaria, Las Palmas, 35016, Spain

  • Hospital Clínico Universitario Lozano Blesa

    Zaragoza, Aragon, 50009, Spain

  • Hospital Clínico Universitario de Valladolid

    Valladolid, Castille and León, 47003, Spain

  • Hospital Costa del Sol

    Málaga, Andalusia, 29603, Spain

  • Hospital General Universitario Gregorio Marañón

    Madrid, 28009, Spain

  • Hospital Nuestra Señora de Sonsoles

    Ávila, Castille and León, 05004, Spain

  • Hospital San Juan de Alicante

    Alicante, Valencia, 03550, Spain

  • Hospital Universitario Central de Asturias

    Oviedo, Principality of Asturias, 33011, Spain

  • Hospital Universitario Donostia

    Donostia / San Sebastian, Basque Country, 20014, Spain

  • Hospital Universitario Quironsalud Madrid

    Madrid, 28223, Spain

  • Hospital Universitario Reina Sofía

    Córdoba, Andalusia, 14004, Spain

  • Hospital Universitario Virgen de Valme

    Seville, Andalusia, 41014, Spain

  • Hospital Universitario de Araba

    Vitoria-Gasteiz, Álava, 01009, Spain

  • Hospital Universitario de Bádajoz

    Bádajoz, Extremadura, 06080, Spain

  • Hospital Universitario de Jaén

    Jaén, Andalusia, 23007, Spain

  • Hospital Universitario de Jeréz De La Frontera

    Cadiz, Andalusia, 11407, Spain

  • Hospital Álvaro Cunqueiro

    Vigo, Galicia, 36213, Spain

  • ICO Badalona

    Barcelona, Catalonia, 08916, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.